Darlifarnib is an investigational next-generation farnesyl transferase inhibitor designed to interfere with cellular pathways ...

Shares of Kura Oncology rose after the company said its potential treatment for clear cell renal cell carcinoma, or ccRCC, demonstrated robust antitumor activity and a manageable safety profile in ...

Kura Oncology (KURA) stock rises as the company posts data from a Phase 1 trial for its experimental kidney cancer therapy, darlifarnib. Read more here.

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI ...

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the ...

Studies have shown that when older adults with cancer get a geriatric assessment, they have: Fewer severe side effects: ...

In this segment on advanced renal cell carcinoma, Dr. McGregor focuses on how clinicians move beyond guideline ...

Researchers from The University of Texas MD Anderson Cancer Center will present breakthrough studies at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Metastatic kidney survival rates don’t predict individual outcomes. A number of factors, including overall health, tumor characteristics, and response to treatment, influence prognosis and survival.

Adults with type 2 diabetes and overweight or obesity who use a GLP-1 receptor agonist have similar risk for kidney cancer as ...

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI ...

Oncologists reveal the number-one sign of bladder cancer, plus how to tell cancer apart from more common issues such as a ...